Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension
Background The tyrosine kinase inhibitor sunitinib causes hypertension associated with reduced nitric oxide (NO) availability, elevated renal vascular resistance, and decreased fractional sodium excretion. We tested whether (1) nitrate supplementation mitigates sunitinib‐induced hypertension and NO...
Saved in:
| Main Authors: | Jeannine Witte, Melanie Mühlbauer, Diana Braun, Antje Steinbach, Janine Golchert, Rainer Rettig, Olaf Grisk |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-09-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.118.009557 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Crystal structures of the catalytic domain of human soluble guanylate cyclase.
by: Charles K Allerston, et al.
Published: (2013-01-01) -
Soluble Guanylate Cyclase Activators as Potential Novel Pad Therapeutics
by: Shaunak Adkar, et al.
Published: (2024-01-01) -
Antithrombotic Activity of an Indolinone Derivative – a Soluble Guanylate Cyclase Stimulator
by: V. V. Bykov, et al.
Published: (2022-09-01) -
Pharmacological effects of a new soluble guanylate cyclase stimulator in experimental pulmonary arterial hypertension
by: V. V. Bykov, et al.
Published: (2023-04-01) -
Soluble Guanylate Cyclase Stimulators for Chronic Thromboembolic Pulmonary Hypertension Patients Treatment: New Data
by: M. A. Simakova, et al.
Published: (2020-05-01)